TScan Therapeutics TCRX
NASDAQ TCRX
$0.14 -0.01 (-6.67%)
At close: Nov 19, 2026 · 4:00 PM EST

TScan Therapeutics (TCRX) EBITDA Margin (2020 - 2026)

Updated

TScan Therapeutics (TCRX) recorded EBITDA Margin of -5520.99% in Q3 2026, down 4075.95 percentage points from -1445.04% a year earlier and down 2686.17 percentage points from the prior quarter.

Analysis

TScan Therapeutics (TCRX) EBITDA Margin (2020 - 2026) Analysis & Trends

On a TTM basis, TScan Therapeutics' EBITDA Margin came in at -2192.98% as of Sep 30, 2026, down 461.85 percentage points year-over-year; for FY2025, it was -1287.29%, up 3354.79 percentage points from FY2024.

  • Annual EBITDA Margin has a five-year change of +1019.90 percentage points (FY2020 to FY2025).
  • Across earlier years, EBITDA Margin came in at -4642.08% in FY2024 (-4223.73 pp), -418.35% in FY2023 (+36.30 pp), -454.64% in FY2022 (-7.54 pp) and -447.11% in FY2021 (+1860.08 pp).
  • The Q3 2026 figure is the lowest quarterly EBITDA Margin since Q2 2024.
  • On a year-over-year basis, EBITDA Margin has declined for three consecutive quarters, with an average year-over-year change of +325.95 percentage points over the last eight quarters.
  • Peak year-over-year performance for EBITDA Margin in the last five years was a gain of 4922.44 percentage points in Q2 2025, against a drop of 5415.75 percentage points in Q2 2024 at the low end.
  • Per Business Quant, the preceding three quarters came in at -2834.82% (Q2 2026), -2896.74% (Q1 2026) and -901.25% (Q4 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 PetVivo Holdings 3,096.39 Bn 3,096.39 Bn 196,075.00 -883.96%
2 Eli Lilly 1,202.70 Bn 1,176.32 Bn 20.46 Bn 36.69%
3 Johnson & Johnson 649.77 Bn 569.63 Bn 17.30 Bn 32.68%
4 AbbVie 507.00 Bn 475.00 Bn 13.12 Bn 46.88%
5 Merck 329.70 Bn 292.64 Bn 13.19 Bn 40.60%
6 Novartis Ag 291.91 Bn 265.14 Bn - -
7 Amgen 236.26 Bn 187.91 Bn 7.58 Bn 46.62%
8 Gilead Sciences 207.15 Bn 182.26 Bn 6.73 Bn 50.63%
9 Gsk 193.54 Bn 176.38 Bn - -
10 TScan Therapeutics 18.87 Mn -434.83 Mn - -5,520.99%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -5,520.99%
Jun 30, 2026 -2,834.82%
Mar 31, 2026 -2,896.74%
Dec 31, 2025 -901.25%
Sep 30, 2025 -1,445.04%
Jun 30, 2025 -1,233.91%
Mar 31, 2025 -1,638.51%
Dec 31, 2024 -5,413.68%
Sep 30, 2024 -3,011.92%
Jun 30, 2024 -6,156.34%
Mar 31, 2024 -5,321.38%
Dec 31, 2023 -271.78%
Sep 30, 2023 -603.60%
Jun 30, 2023 -740.60%
Mar 31, 2023 -312.27%
Dec 31, 2022 -537.64%
Sep 30, 2022 -455.75%
Jun 30, 2022 -346.13%
Mar 31, 2022 -495.47%
Dec 31, 2021 -457.60%
API Access

TScan Therapeutics EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=TCRX&period=max&api_key=YOUR_API_KEY